Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 220

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis

Kruger, Peter, Bailey, Michael, Bellomo, Rinaldo, Cooper, David James, Harward, Meg, Higgins, Alisa, Howe, Belinda, Jones, Darryl, Joyce, Chris, Kostner, Karam, McNeil, John, Nichol, Alistair, Roberts, Michael S., Syres, Gillian, Venkatesh, Bala, for the ANZ-STATInS Investigators–ANZICS Clinical Trials Group · 2013 · American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Observational studies link statin therapy with improved outcomes in patients with severe sepsis. OBJECTIVES: To test whether atorvastatin therapy affects biologic and clinical outcomes in critically ill patients with severe sepsis. METHODS: Phase II, multicenter, prospective, randomized, double-blind, placebo-controlled trial stratified by site and prior statin use. A cohort of 250 critically ill patients (123 statins, 127 placebo) with severe sepsis were administrated either atorvastatin (20 mg daily) or matched placebo. MEASUREMENTS AND MAIN RESULTS: There was no difference in IL-6 concentrations (primary end point) between the atorvastatin and placebo groups (P = 0.76) and no interaction between treatment group and time to suggest that the groups behaved differently over time (P = 0.26). Baseline plasma IL-6 was lower among previous statin users (129 [87-191] vs. 244 [187-317] pg/ml; P = 0.01). There was no difference in length of stay, change in Sequential Organ Failure Assessment scores or mortality at intensive care unit discharge, hospital discharge, 28- or 90-day (15% vs. 19%), or adverse effects between the two groups. Cholesterol was lower in patients treated with atorvastatin (2.4 [0.07] vs. 2.6 [0.06] mmol/L; P = 0.006). In the predefined group of 77 prior statin users, those randomized to placebo had a greater 28-day mortality (28% vs. 5%; P = 0.01) compared with those who received atorvastatin. The difference was not statistically significant at 90 days (28% vs. 11%; P = 0.06). CONCLUSIONS: Atorvastatin therapy in severe sepsis did not affect IL-6 levels. Prior statin use was associated with a lower baseline IL-6 concentration and continuation of atorvastatin in this cohort was associated with improved survival. Clinical trial registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12607000028404).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201209-1718oc

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 220

Metadata

Authors
Kruger, P., Bailey, M., Bellomo, R., Cooper, D. J., Harward, M., Higgins, A., Howe, B., Jones, D., Joyce, C., Kostner, K., McNeil, J., Nichol, A., Roberts, M. S., Syres, G., Venkatesh, B., & for the ANZ-STATInS Investigators–ANZICS Clinical Trials Group
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2013-04-01
Volume
187
Issue
7
Pages
743-750
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2036295658
Cited by
220
References
5
FWCI
19.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis. https://app.cochat.ai/papers/10.1164/rccm.201209-1718oc
The paper
Kruger, P., Bailey, M., Bellomo, R., Cooper, D. J., Harward, M., Higgins, A., Howe, B., Jones, D., Joyce, C., Kostner, K., McNeil, J., Nichol, A., Roberts, M. S., Syres, G., Venkatesh, B., & for the ANZ-STATInS Investigators–ANZICS Clinical Trials Group. (2013). A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201209-1718oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.